(Difference between revisions)
|
|
Line 63: |
Line 63: |
| | | |
| ==Article Collections== | | ==Article Collections== |
− | {{slink|l=http://www.moremed.org/MedlineBsuchtPMC.php?Q=%28BMC+Pharmacol+Toxicol%5BJOUR%5D+AND+16%5BVI%5D+AND+Suppl%201%5BIP%5D%29&Z0=0&ZL=150&Y=&MTB=1&px1=proxy.nationallizenzen.de&px2=&px3=&px4= |Congress Abstracts on Guanylate Cyclase Inhibition 2015 |c= }} | + | {{slink|l=http://www.moremed.org/MedlineBsuchtPMC.php?Q=%28BMC+Pharmacol+Toxicol%5BJOUR%5D+AND+16%5BVI%5D+AND+Suppl%201%5BIP%5D%29&Z0=0&ZL=150&Y=&MTB=1&px1=proxy.nationallizenzen.de&px2=&px3=&px4= |t=Congress Abstracts on Guanylate Cyclase Inhibition 2015 |c= }} |
| | | |
| ==Links== | | ==Links== |
Revision as of 19:56, 2 February 2016
Core OA papers on Riociguat
Journal article, free access
|
GET 2014. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct
|
Journal article, free access
|
GET 2015. Riociguat: Something new in pulmonary hypertension therapeutics? Extract PDF direct
|
Journal article, free access
|
GET 2014. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct
|
Journal article, free access
|
GET 2013. Riociguat for the treatment of pulmonary arterial hypertension Extract PDF direct
|
Journal article, free access
|
GET 2013. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension Extract PDF direct
|
Journal article, free access
|
GET 2010. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Extract PDF direct
|
Journal Paper, restricted access
|
GET 2014. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension Extract PDF direct
|
General outline of Pulmonary Hypertension
Journal article, free access
|
GET 2013. Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension Extract PDF direct
|
Journal article, free access
|
GET 2015. Medical treatment update on pulmonary arterial hypertension Extract PDF direct
|
Journal article, free access
|
GET 2015. The molecular targets of approved treatments for pulmonary arterial hypertension Extract PDF direct
|
Journal article, free access
|
GET 2015. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Extract PDF direct
|
Journal article, free access
|
GET 2014. Drug Therapy for Chronic Thromboembolic Pulmonary Hypertension: A Review of the Comparative Clinical Effectiveness Extract PDF direct
|
Journal article, free access
|
GET 2014. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension Extract PDF direct
|
Journal article, free access
|
GET 2014. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension Extract PDF direct
|
Journal article, free access
|
GET 2013. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Extract PDF direct
|
Journal article, free access
|
GET 2014. Respiratory review of 2014: pulmonary thromboembolism Extract PDF direct
|
Journal article, free access
|
GET 2014. Novel and emerging therapies for pulmonary hypertension Extract PDF direct
|
Journal article, free access
|
GET 2013. Chronic thromboembolic pulmonary hypertension: role of medical therapy Extract PDF direct
|
Journal Paper, restricted access
|
GET 2015. Pulmonary arterial hypertension: a review in pharmacotherapy Extract PDF direct
|
Mechanism of action
Journal article, free access
|
GET 2010. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Extract PDF direct
|
Journal article, free access
|
GET 2009. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Extract PDF direct
|
Journal article, free access
|
GET 2008. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Extract PDF direct
|
Journal Paper, restricted access
|
GET 2013. The chemistry and biology of soluble guanylate cyclase stimulators and activators Extract PDF direct
|
Journal Paper, restricted access
|
GET 2009. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension Extract PDF direct
|
Journal Paper, restricted access
|
GET 2013. Soluble guanylate cyclase stimulators in pulmonary hypertension Extract PDF direct
|
Journal Paper, restricted access
|
GET 2009. NO-independent, haem-dependent soluble guanylate cyclase stimulators Extract [{| class="wikitable"; style="border: 1pt"
|
Journal Paper, restricted access
|
GET 2013. Soluble guanylate cyclase stimulators in pulmonary hypertension Extract PDF direct
|
PDF direct]
|}
Some trials
Journal Paper, restricted access
|
GET 2015. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) Extract PDF direct
|
Journal Paper, restricted access
|
GET 2015. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Extract PDF direct
|
Journal article, free access
|
GET 2014. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study Extract PDF direct
|
Journal article, free access
|
GET 2014. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema Extract PDF direct
|
Journal article, free access
|
GET 2015. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease Extract PDF direct
|
Journal article, free access
|
GET 2015. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct
|
Journal article, free access
|
GET 2013. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT Extract PDF direct
|
Journal article, free access
|
GET 2013. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study Extract PDF direct
|
Journal article, free access
|
GET 2015. Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food Extract [ PDF direct]
|
Nephrology-related data
Journal Paper, restricted access
|
GET 2013. The cyclic GMP-dependent protein kinase Ialpha suppresses kidney fibrosis Extract PDF direct
|
Journal Paper, restricted access
|
GET 2015. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies Extract PDF direct
|
Journal article, free access
|
GET 2015. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence Extract PDF direct
|
Journal article, free access
|
GET 2011. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats Extract PDF direct
|
Journal Paper, restricted access
|
GET 2010. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models Extract PDF direct
|
Article Collections
Links
Books